BLOOD CANCER UK RESEARCH

1. BLOOD CANCER UK RESEARCH 2024-04-03 → present
2. BLOODWISE 2015-04-02 → 2024-04-03
3. LEUKAEMIA & LYMPHOMA RESEARCH 2009-12-10 → 2015-04-02
4. LEUKAEMIA RESEARCH FUND LIMITED 1962-10-17 → 2009-12-10

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

Crowe U.K. LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Trustees regularly review the risks and uncertainties facing Blood Cancer UK and the Charity's financial plans. The Charities reserves policy has been established to provide resilience against the financial effects of reasonable variations from plans and uncertainties. The continuing cost-of-living crisis, the step change in inflation in the last few years, and the economic uncertainty as a result of the increase of global tariffs has created a difficult operating environment for a lot of charities. Our forward planning is informed by extensive scenario planning and has included different models for economic recovery and changes in consumer and supporter behaviour. As part of the Trustees' review of going concern, budgets have been prepared for the financial years to 31 March 2026, as well as high-level financial plans until 31 March 2030. These financial plans have been used to assess the expected balance sheet position for each accounting period until 31 March 2030. The expected balance sheet position is positive, with liquid resources sufficient to cover all outstanding liabilities as they fall due. Based on these reviews, the Trustees consider that the Charity has adequate resources to continue in operational existence for at least 12 months from the date of this report. Accordingly, they continue to adopt the going concern basis of accounting in preparing the annual accounts.”

Group structure

1. BLOOD CANCER UK RESEARCH · parent
   1. Bloodwise Trading Limited 100% · United Kingdom · Christmas card and sportswear retailing and the management of royalties arising from intellectual property in research and the Calendar Girls activities.
   2. Bloodwise Ltd 100% · United Kingdom · dormant
   3. Leukaemia & Lymphoma Research Limited 100% · United Kingdom · dormant

Significant events

• “Thanks to your support, our income reached a staggering £21.1 million for the first time in a decade.”
• “we awarded £10.1 million to research, an increase of 65% compared to last year”
• “launched several new grant schemes”
• “The launch of our Blood Cancer Action Plan was a pivotal moment”
• “our new direct referral service means even more people have been able to access our support.”
• “awarded over £1.3 million in funding to our first four Early Career Fellows”
• “fund five major projects with the potential to transform lives”
• “Launch a pilot to see how healthcare professionals and people affected by blood cancer might use a direct referral to us from NHS clinical teams. Thanks to a successful pilot, 348 people were referred to us across the year”
• “signed new co-funding agreements that will see us award a further £1.3 million in partnership with other funders, unlocking £2.3 million of additional research investment in the years ahead.”
• “awarded funding to: 12 innovative pilot projects, 8 project grants, 5 transformational research awards, 4 early career fellowships, 2 clinical trials”
• “new UK Blood Cancer Research Network, which will set priorities for clinical research and support scientists to deliver research that could change lives.”
• “The MELODY study, led by Dr Michelle Willicombe at Imperial University, showed that repeat Covid-19 vaccines offered vital protection for those with weakened immune systems”
• “US drug regulator granted a licence for a new type of CAR-T cell therapy to treat a particularly aggressive type of acute lymphoblastic leukaemia.”
• “published our Blood Cancer Action Plan: a comprehensive blueprint for addressing this challenge”
• “delighted to win the Association of Medical Research Charities' Impactful Advocacy Award.”
• “expanded our blood cancer information this year to reach more people and support disadvantaged groups, creating a suite of health information in five community languages.”
• “developed new resources, such as: Information on infection risk, including a printed alert card; New resources on specific types of blood cancer; A new 'Black with blood cancer' web page”
• “team of specialist nurses provided tailored support and information to 1,825 people, 14% more than last year.”
• “saw huge growth in people using our online community forum, with 1,665 new members”
• “expanded our Clinical Trials Support Service”
• “team conducted searches for 177 people seeking to join a clinical trial, identifying potentially suitable trials for 86 people.”
• “began a key project working closely with people in Black and Pakistani communities to understand their experience of accessing clinical trials.”
• “this year 1,192 people completed our e-learning course to equip new starters in haemato-oncology care with understanding and awareness”
• “began working with University Hospitals of North Midlands on a new pilot, giving staff the tools to directly refer patients to us when they are diagnosed.”
• “had 349 new referrals in the scheme's first year, with excellent feedback. The pilot showed people not only engaged with our support and resources, but were more confident in understanding their diagnosis and finding support as a result.”
• “service is now live in 12 hospital trusts across the UK.”
• “Fundraised income grew to £19.2 million”
• “received £2 million from Brit Insurance to fund research into myeloma research, marking one of our largest ever corporate donations.”
• “received over £500,000 from pharmaceutical companies to help fund our support services and our advocacy work.”
• “received £7.5 million from people who left gifts in their Wills.”
• “The number of people who have pledged to support us in this way grow by more than 40%.”
• “960 new supporters to our community of people choosing to raise money in their own way.”
• “Fireflies Cycling team raising £86,000”
• “Laugh for Leukaemia event raised £12,500”
• “new fundraising event, 'Walk the World', challenged people to collectively walk the distance around the world... raising an incredible £127,000 together.”
• “Christmas campaign linked together several fundraising activities, topped off by a carol concert at St Paul's Cathedral in London that raised over £200,000.”
• “More than 2,000 people joined us to take part in our annual Walk of Light event in Birmingham, or to take on their own walks across the UK.”
• “awarded Best Companies' 3-star accreditation, recognising us as a workplace with world class levels of engagement, and we were listed as one of the top 5 best charities to work for in the UK.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +14.1%

  £18,460,000 → £21,062,000

• Cash

  +60.4%

  £2,662,000 → £4,269,000

• Net assets

  -0.4%

  £20,180,000 → £20,100,000

• Employees

  +4%

  126 → 131

• Profit before tax

  -50.5%

  £1,694,000 → £839,000

• Wages

  +7.1%

  £5,651,000 → £6,054,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers